Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04921904
PHASE1/PHASE2

Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

Sponsor: Baylor Research Institute

View on ClinicalTrials.gov

Summary

CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy resistant diseases.

Official title: Phase I/II Study of Abemaciclib + Ramucirumab in Metastatic Esophageal/Gastroesophageal Junction Carcinomas

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

8

Start Date

2021-06-11

Completion Date

2026-06

Last Updated

2026-02-05

Healthy Volunteers

No

Interventions

DRUG

Abemaciclib

150mg dose administered orally twice daily every day

DRUG

Ramucirumab

8mg/kg iv every 2 weeks until evidence of disease

Locations (1)

Baylor University Medical Center, Charles A Sammons Cancer Center

Dallas, Texas, United States